621 related articles for article (PubMed ID: 18165640)
1. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
[TBL] [Abstract][Full Text] [Related]
3. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
Yamamoto H; Sekine I; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Oncology; 2008; 75(3-4):169-74. PubMed ID: 18827494
[TBL] [Abstract][Full Text] [Related]
5. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy.
Semrau S; Klautke G; Virchow JC; Kundt G; Fietkau R
Respir Med; 2008 Feb; 102(2):210-8. PubMed ID: 17980571
[TBL] [Abstract][Full Text] [Related]
6. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.
Jatoi A; Hillman S; Stella P; Green E; Adjei A; Nair S; Perez E; Amin B; Schild SE; Castillo R; Jett JR;
J Clin Oncol; 2005 Dec; 23(36):9113-9. PubMed ID: 16361618
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
[TBL] [Abstract][Full Text] [Related]
10. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
Alam N; Shepherd FA; Winton T; Graham B; Johnson D; Livingston R; Rigas J; Whitehead M; Ding K; Seymour L
Lung Cancer; 2005 Mar; 47(3):385-94. PubMed ID: 15713522
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
Hensing TA; Schell MJ; Lee JH; Socinski MA
Lung Cancer; 2005 Feb; 47(2):253-9. PubMed ID: 15639724
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.
Di Maio M; Lama N; Morabito A; Smit EF; Georgoulias V; Takeda K; Quoix E; Hatzidaki D; Wachters FM; Gebbia V; Tsai CM; Camps C; Schuette W; Chiodini P; Piccirillo MC; Perrone F; Gallo C; Gridelli C
Eur J Cancer; 2010 Mar; 46(4):735-43. PubMed ID: 20045311
[TBL] [Abstract][Full Text] [Related]
14. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
15. Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer.
Zhang Z; Xu F; Wang S; Li N; Wang C
Lung Cancer; 2008 Jun; 60(3):434-40. PubMed ID: 18036699
[TBL] [Abstract][Full Text] [Related]
16. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
Imaizumi M;
Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
[TBL] [Abstract][Full Text] [Related]
17. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC).
Firat S; Pleister A; Byhardt RW; Gore E
Am J Clin Oncol; 2006 Jun; 29(3):252-7. PubMed ID: 16755178
[TBL] [Abstract][Full Text] [Related]
18. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection.
Wang CY; Lin YS; Tzao C; Lee HC; Huang MH; Hsu WH; Hsu HS
Eur J Cardiothorac Surg; 2007 Dec; 32(6):877-81. PubMed ID: 17920921
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]